 OSLO, Norway--BUSINESS WIRE--- ULTI AACR2021--Ultimovacs ASA Ultimovacs, ticker ULTI, announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Companys proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, Nivolumab and ipilimumab 